When a physician in the Season 2 premiere of the medical drama The Pitt invoked PECARN protocols while evaluating a febrile infant in the emergency department, millions of viewers witnessed something remarkable: a decade of painstaking research distilled into a single clinical decision. The landmark study behind that moment, “A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections” (PMID 30776077), is exactly the kind of work PECARN was built to produce. And in 2026, we’re celebrating 25 years of it.
From Research to the Bedside and Now to Prime Time
The febrile infant prediction rule that The Pitt depicted isn’t a hypothetical future tool. It’s embedded in real emergency departments, informing real decisions for real families every day. The PECARN rule uses three readily available lab values, a urinalysis, a white blood cell measurement, and a procalcitonin level, to identify infants at low risk for serious bacterial infections, helping clinicians avoid unnecessary hospitalizations, invasive procedures, and antibiotic exposure. Seeing it depicted in a nationally watched drama signals that evidence-based pediatric care has reached public consciousness.
Before this rule existed, most febrile infants under 60 days old were automatically admitted to the hospital and started on antibiotics while awaiting culture results. This was a precaution that, while well-intentioned, subjected many healthy babies to painful procedures and unnecessary treatment. The PECARN rule gave clinicians a validated, evidence-based way to identify which infants were at low enough risk to be managed more conservatively, using just three lab values: a urine test, an absolute neutrophil count (a measure of infection-fighting white blood cells), and a procalcitonin level (a protein that rises in response to bacterial infection). Together, these markers help distinguish the babies who truly need aggressive workup from those who can be safely monitored with close follow-up.
What Is PECARN?
The Pediatric Emergency Care Applied Research Network (PECARN) is the nation’s only federally funded research network dedicated exclusively to emergency care for children. Supported by the Health Resources and Services Administration’s Emergency Medical Services for Children (EMSC) Program, it brings together investigators across 18 emergency departments and 9 EMS agencies nationwide, all working toward one goal: ensuring that when a child arrives in the emergency department, the decisions made on their behalf are grounded in the best available science.
Before PECARN, many high-stakes decisions in pediatric emergency medicine relied on clinical intuition, tradition, or protocols designed for adults and adapted imperfectly for kids. Should this infant have a spinal tap? Does this child with a head bump need a CT scan? When should we worry, and when can we safely wait and watch? PECARN changed how we answer those questions.
25 Years of Impact
PECARN research has reshaped care across the full spectrum of pediatric emergencies: head trauma, seizures, asthma, and more. Studies have reduced unnecessary radiation exposure, supported shared decision-making with families, and informed national clinical practice guidelines.
This work also supports the National Pediatric Readiness Project (NPRP) and the National Prehospital Pediatric Readiness Project, two EMSC-led initiatives to improve emergency readiness for children. High pediatric readiness in EDs has been associated with up to 76% reduction in mortality risk for critically ill children, and 60% for critically injured children. This spring, the NPRP is launching a nationwide survey for EDs to assess their pediatric readiness.
None of this happens without the investigators, clinicians, research staff, EMS partners, and families who have participated in PECARN studies over 25 years. That contribution is what makes the science possible.
To learn more, visit pecarn.org.
